Participant flow

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies · Source last updated 2024-04-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).

   id

   FG000

   title

   RDT Cohort - Castration-Resistant Prostate Cancer (CRPC)

2. description

   Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).

   id

   FG001

   title

   RDT Cohort - Melanoma

3. description

   Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).

   id

   FG002

   title

   RDT Cohort - Non-Small Cell Lung Cancer (NSCLC)

4. description

   Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).

   id

   FG003

   title

   RDT Cohort - Pancreatic Cancer

5. description

   Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).

   id

   FG004

   title

   RDT Cohort - Gastric/Gastroesophageal Junction Cancer (GEJ)

6. description

   Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).

   id

   FG005

   title

   RDT Cohort - Hepatocellular Carcinoma (HCC)

7. description

   Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).

   id

   FG006

   title

   RDT Cohort - Small Cell Lung Cancer (SCLC)

8. description

   Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).

   id

   FG007

   title

   RDT Cohort - Ovarian Cancer

9. description

   Eligible subjects with advanced solid tumors received open-label cabozantinib at a starting daily dose of 100 mg (freebase weight).

   id

   FG008

   title

   RDT Cohort - Metastatic Breast Cancer (MBC)

10. description

    Subjects received a single oral daily dose of cabozantinib at 100 mg.

    id

    FG009

    title

    NRE Cohort - CRPC 100 mg

11. description

    Subjects received a single oral daily dose of cabozantinib at 39.4 mg.

    id

    FG010

    title

    NRE Cohort - CRPC 39.4 mg

12. description

    Subjects received a single oral daily dose of cabozantinib at 100 mg.

    id

    FG011

    title

    NRE Cohort - Ovarian Cancer 100mg

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         171

      2. group Id

         FG001

         num Subjects

         77

      3. group Id

         FG002

         num Subjects

         60

      4. group Id

         FG003

         num Subjects

         20

      5. group Id

         FG004

         num Subjects

         21

      6. group Id

         FG005

         num Subjects

         41

      7. group Id

         FG006

         num Subjects

         21

      8. group Id

         FG007

         num Subjects

         70

      9. group Id

         FG008

         num Subjects

         45

      10. group Id

          FG009

          num Subjects

          93

      11. group Id

          FG010

          num Subjects

          51

      12. group Id

          FG011

          num Subjects

          60

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         156

      2. group Id

         FG001

         num Subjects

         66

      3. group Id

         FG002

         num Subjects

         47

      4. group Id

         FG003

         num Subjects

         16

      5. group Id

         FG004

         num Subjects

         19

      6. group Id

         FG005

         num Subjects

         36

      7. group Id

         FG006

         num Subjects

         20

      8. group Id

         FG007

         num Subjects

         60

      9. group Id

         FG008

         num Subjects

         41

      10. group Id

          FG009

          num Subjects

          87

      11. group Id

          FG010

          num Subjects

          48

      12. group Id

          FG011

          num Subjects

          54

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         15

      2. group Id

         FG001

         num Subjects

         11

      3. group Id

         FG002

         num Subjects

         13

      4. group Id

         FG003

         num Subjects

         4

      5. group Id

         FG004

         num Subjects

         2

      6. group Id

         FG005

         num Subjects

         5

      7. group Id

         FG006

         num Subjects

         1

      8. group Id

         FG007

         num Subjects

         10

      9. group Id

         FG008

         num Subjects

         4

      10. group Id

          FG009

          num Subjects

          6

      11. group Id

          FG010

          num Subjects

          3

      12. group Id

          FG011

          num Subjects

          6

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice